Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

T cell receptor β-chain-targeting chimeric antigen receptor T cells against T cell malignancies
Fanlin Li, Huihui Zhang, Wanting Wang, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 23

Showing 23 citing articles:

From bench to bedside: the history and progress of CAR T cell therapy
Aroshi Mitra, Amrita Barua, Luping Huang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 186
Immune Checkpoint Inhibitors — The Need for Innovation
P. Connor Johnson, Justin F. Gainor, Ryan J. Sullivan, et al.
New England Journal of Medicine (2023) Vol. 388, Iss. 16, pp. 1529-1532
Closed Access | Times Cited: 28
CAR-T cell therapy: Where are we now, and where are we heading?
Jiayi Wang, Liang Wang
Blood Science (2023) Vol. 5, Iss. 4, pp. 237-248
Open Access | Times Cited: 28
M6A-mediated-upregulation of lncRNA BLACAT3 promotes bladder cancer angiogenesis and hematogenous metastasis through YBX3 nuclear shuttling and enhancing NCF2 transcription
Jinbo Xie, Hui Zhang, Keyi Wang, et al.
Oncogene (2023) Vol. 42, Iss. 40, pp. 2956-2970
Open Access | Times Cited: 25
The emerging scenario of immunotherapy for T-cell Acute Lymphoblastic Leukemia: advances, challenges and future perspectives
Daniele Caracciolo, Antonia Mancuso, Nicoletta Polerà, et al.
Experimental Hematology and Oncology (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 19
CAR-iNKT cells targeting clonal TCRVβ chains as a precise strategy to treat T cell lymphoma
Aileen Rowan, Kanagaraju Ponnusamy, Hongwei Ren, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 18
Generation and optimization of off-the-shelf immunotherapeutics targeting TCR-Vβ2+ T cell malignancy
Jingjing Ren, Xiaofeng Liao, Julia M. Lewis, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 5
Thermoresponsive Polypeptide Fused L‐Asparaginase with Mitigated Immunogenicity and Enhanced Efficacy in Treating Hematologic Malignancies
Sanke Zhang, Yuanzi Sun, Longshuai Zhang, et al.
Advanced Science (2023) Vol. 10, Iss. 23
Open Access | Times Cited: 12
T-cell Redirecting Therapies in Haematological malignancies: Current Developments and Novel Strategies for Improved Targeting
Georgina S.F. Anderson, Michael A. Chapman
Molecular Therapy (2024) Vol. 32, Iss. 9, pp. 2856-2891
Open Access | Times Cited: 4
Advances in DNA-empowered membrane surface engineering for artificial manipulation and visual analysis of cell-cell communication
Tian Zhang, Xun Guo, Jiao Zheng, et al.
TrAC Trends in Analytical Chemistry (2025), pp. 118280-118280
Closed Access
Engaging T cells for cleanup
Roman V. Mungalov, N.V. Mushenkova, Dmitriy M. Chudakov, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
AI-Driven CRISPR-Cas9 sgRNA Design for PDCD1, TRAC, and B2M Knockout to Improve CAR T Cell Therapy
kirti sharma
Research Square (Research Square) (2025)
Closed Access
Targeted drug delivery system for Golgi apparatus's diseases
Yongxin Xu, Yi Jin, Yuting Huang, et al.
Engineered Regeneration (2024)
Open Access | Times Cited: 2
Novel and multiple targets for chimeric antigen receptor-based therapies in lymphoma
Yifan Pang, Nilanjan Ghosh
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 1
T cell receptor-directed antibody-drug conjugates for the treatment of T cell-derived cancers
Katrin Schoenfeld, Jan Habermann, Philipp Wendel, et al.
Deleted Journal (2024) Vol. 32, Iss. 3, pp. 200850-200850
Closed Access | Times Cited: 1
Cancer cell targeting by CAR-T cells: A matter of stemness
Caterina D’Accardo, Gaetana Porcelli, Laura Rosa Mangiapane, et al.
Frontiers in Molecular Medicine (2022) Vol. 2
Open Access | Times Cited: 6
Editorial: Twenty Years On from Sequencing the Human Genome, Personalized/Precision Oncology Prepares to Meet the Challenges of Checkpoint Inhibitor Therapy
Dinah V. Parums
Medical Science Monitor (2023) Vol. 29
Open Access | Times Cited: 1
Chimeric antigen receptor T cells march into T cell malignancies
Jie Tang, Xudong Zhao
Journal of Cancer Research and Clinical Oncology (2023) Vol. 149, Iss. 14, pp. 13459-13475
Closed Access | Times Cited: 1
SOHO State of the Art Updates and Next Questions | CAR T Cells in T Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
Daniil Shmidt, Maksim Mamonkin
Clinical Lymphoma Myeloma & Leukemia (2024)
Closed Access
TCRvβ8 chimeric antigen receptor natural killer cells exhibit potent preclinical activity against T‐cell malignancies
Lianjun He, Yinmei He, Ye He, et al.
Clinical and Translational Medicine (2024) Vol. 14, Iss. 8
Open Access
A Yale Dermatology Perspective on Cutaneous T-Cell Lymphoma: Historical Reflection to Emerging Therapies
Madisen A. Swallow, Richard L. Edelson, Michael Girardi
Clinics in Dermatology (2024)
Closed Access
Development of a recombinant human IgG1 monoclonal antibody against the TRBV5-1 segment of the T cell receptor for the treatment of mature T cell neoplasms
Michele Pitaro, Giovanni Antonini, Alessandro Arcovito, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access
Reinforcement learning-guided control strategies for CAR T-cell activation and expansion
Sakib Ferdous, Ibne Farabi Shihab, Ratul Chowdhury, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access
Page 1

Scroll to top